<学術雑誌論文>
乳癌ゲノム医療

作成者
本文言語
出版者
発行日
収録物名
開始ページ
終了ページ
出版タイプ
アクセス権
JaLC DOI
概要 During the 21st century, we have witnessed the advancement in technological innovations and significant reduction in the cost of microarrays, which comprehensively analyze gene expression in cancer ce...lls. The field of breast cancer treatment was the first to reap the benefit of this development. The practice of breast cancer has evolved tremendously since the establishment of the era of gene expression profiling. In line with this, “Precision Medicine Initiative” was launched in the United States last January 20, 2015, during President Obamaʼs State of the Union address. This program shifted the direction of treatment from the ”one-size-fits-all-approach” to individualized precise medicine. Even in Japan, the era of tailoring therapies in a patient has started. Patients and tumors are assessed and analyzed individually from a molecular and genetic standpoint in order to select and provide the best and optimal treatment strategy based on the gathered information. In this article, we summarize the genetic multi-panel tests developed so far (Prosigna®, EndoPredict®, Oncotype DX®, MammaPrint®, Curebest 95 GC Breast®, etc.) and substantiate its present and prospective clinical applications in breast cancer.続きを見る
目次 はじめに
1.Prosigna® (PAM50 : Prediction analysis of microarray 50, ROR : Risk of recurrence)
2.EndoPredict® (12-gene risk score)
3.OncotypeDX Breast Recurrence Score®
(1) NSABP B14
(2) NSABP B-20
(3) SWOG 8814
(4) JBCRG-TR003
(5) TransATAC
(6) TAILORx
(7) WSG PlanB
(8) SEER database
4. MammaPrint®
5.Curebest 95GC Breast®
6. 病期(Staging)への影響
7. Myriad myRiskTM:生殖細胞系列遺伝子パネル検査
8.遺伝子パネル検査
9. がんゲノム医療中核拠点病院
おわりに
続きを見る

本文ファイル

pdf p015 pdf 2.12 MB 3,751  

詳細

PISSN
NCID
レコードID
査読有無
主題
タイプ
登録日 2018.10.25
更新日 2021.03.03

この資料を見た人はこんな資料も見ています